ABBV-744 CANCER TREATMENT CLINICAL TRIALS - AN OVERVIEW

In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Members will receive treatment until eventually condition progression or the individuals are not able to tolerate the study drugs.Ubiquitin-connected proteins that control The steadiness of important super enhancer-m